Biotech Startups

Airiver Medical is a clinical-stage company developing a Drug Coated Balloon to treat respiratory tract conditions such as airway stenosis and chronic sinus inflammation. The investigational device aims to create sustained patency with better outcomes and fewer treatments for patients with these conditions.

1 investor

1 investor

Airway Therapeutics is a biotech company developing inhaled therapeutics for inflammatory and infectious lung diseases, including programs targeting bronchopulmonary dysplasia, acute respiratory distress syndrome, and pulmonary fibrosis.

1 investor

Aitia builds in silico models of human disease biology using a causal AI platform that combines multiomic and clinical patient data with supercomputing to support drug discovery and development. It partners with biopharma companies to identify novel drug targets across diseases such as oncological, neurodegenerative, immunological, and cardiometabolic conditions.

1 investor

AIVITA Biomedical is a biotechnology company developing personalized vaccines using an autologous cell therapy platform, including a pan-antigenic cancer vaccine that targets all neoantigens and a multi-pathogen vaccine kit for infectious disease prevention. Its work draws on expertise in stem cell growth and high-purity cell differentiation.

1 investor

Aizen is an AI-native biotechnology company that designs novel oral peptides using non-canonical amino acids and an AI platform called DaX to treat chronic immune disorders. The company develops both proprietary therapeutics and partners with biopharma companies to advance gut-restricted and systemic oral biologics.

1 investor

Ajax Health is a life science investment firm that manages a portfolio of medtech, biopharma, and diagnostic companies. The firm focuses on sourcing, due diligence, and active management of investments in the healthcare and medical technology sectors.

1 investor

Ajaya Bio develops bispecific therapies designed to eliminate disease-driving cells while sparing healthy ones, using its BOLT-360 discovery platform built around hybrid binders, precise activation, and advanced linkers. The company operates in the biotherapeutics field.

1 investor

AKAN Biosciences is a biotechnology and cellular therapy company developing injectable, adipose stem cell-based regenerative products to treat degenerative diseases and injuries. Its lead product, StroMel, is in Phase 2 clinical trials for knee osteoarthritis, with additional trials planned for other joints, wound healing, Crohn's disease, sports injuries, and autism.

1 investor

Akanocure is a drug development company using a proprietary chemistry platform to create novel small-molecule therapies, with a focus on orphan and unmet needs in oncology and blocking metastatic processes. Its work spans chemical methodology development and classic drug discovery for cancer treatments.

1 investor

Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates (ADCs) built on a proprietary PH1 spliceosome-modulating payload that disrupts RNA splicing in cancer cells. Its pipeline includes AKTX-101, targeting the Trop2 receptor, and AKTX-102, targeting CEACAM5 across solid tumors.

1 investor

Akira Bio develops therapies for people living with sickle cell disease and other hemoglobinopathies. It is a biotechnology company focused on treatments for blood disorders.

1 investor

Albutec develops extracorporeal albumin dialysis (ECAD) technology, including its MaxiCycler device with redesigned adsorbent and tubing, to support or replace liver function in patients with acute and acute-on-chronic liver failure. The platform is intended for use by doctors, nurses, and critical care medical teams treating liver patients.

1 investor

Alcheme Bio develops precision enzyme systems that improve flavor and functionality in protein ingredients during manufacturing processing. The company's enzyme technology reduces off-notes and bitterness in plant proteins, upcycled materials, and emerging protein systems for food manufacturers.

1 investor

Alchemedicine is a drug discovery company focused on research and development of new small-molecule medicines, using its proprietary synthesis technology HiSAP® to improve on existing drugs' weak efficacy, side effects, and pharmacokinetics. It pursues multiple simultaneous R&D programs across disease areas with high unmet medical need.

1 investor

Alchemi combines AI with scientific expertise to accelerate drug development timelines and reduce time-to-market for therapies. The company serves pharmaceutical development teams and aims to lower drug costs and improve access to medicines.

1 investor

Biogen develops and markets therapies for spinal muscular atrophy (SMA), including FDA-approved treatments and the investigational ThecaFlex DRx System, an implantable intrathecal drug delivery device. The company serves patients and families affected by SMA and other neuromuscular conditions globally.

1 investor

1 investor

AlgaeCytes cultivates microalgae using enclosed photobioreactors to produce high-value natural ingredients, including Omega-3 EPA oils, for the health and wellness industry. The company targets sustainable alternatives to fish oil and other conventional ingredient sources for supplements, food, and cosmetics applications.

1 investor

Algaeing produces textile dyes and fibers from algae, a renewable microorganism, replacing synthetic dyes in the fashion industry. The company partners with algae growers to create sustainable, biodegradable materials that retain algae's botanical properties.

1 investor

AlgaFilm develops an algae-based biofilm technology for wastewater treatment that recovers nutrients as a sustainable alternative to conventional treatment methods. The company targets wastewater utilities and treatment facilities globally with its innovative process.

1 investor

JRS is a family-owned company that manufactures and markets plant-based functional additives for food, pet food, pharmaceuticals, personal care, and technical applications globally. The group operates 3,000+ employees across 20+ international commercial entities, 7 R&D centers, and 50+ production facilities.

1 investor

Alganex supplies certified organic Spirulina platensis powder, a nutrient-dense microalgae product cultivated in Italy, for use as a food supplement, functional ingredient, animal feed component, and cosmetic ingredient across B2B markets. The powder is valued for its high protein content, essential amino acids, and phycocyanin (blue pigment) concentration.

1 investor

AlgenAir produces the aerium, a home device that uses algae to reduce indoor carbon dioxide and increase oxygen while generating organic fertilizer from the algae byproduct. It serves household users seeking improved air quality and plant enthusiasts.

1 investor